Fig. 8: Sivelestat treatment selectively modulates innate immune cell populations in lung and spleen. | Experimental & Molecular Medicine

Fig. 8: Sivelestat treatment selectively modulates innate immune cell populations in lung and spleen.

From: Prolonged immune activation in post-acute sequelae of SARS-CoV-2: neutrophil dynamics and therapeutic insights

Fig. 8: Sivelestat treatment selectively modulates innate immune cell populations in lung and spleen.

a A schematic overview of drug administration and flow cytometry analysis. Created with BioRender.com. b, c Body weight change data of ‘Non-treat’ (SARS2, SARS-CoV-2 infection only, n = 40) (b) and Sivelestat/2% DMSO in a saline treatment (n = 50) (c). d Proportion of recovery (blue), non-recovery (yellow) and death (red) of each group. e, f Percentage of B cells (CD79⁺), T cells (CD3⁺), monocytes/MQs (CD11b⁺CD14⁺) and neutrophils (CD11b⁺Ly6G⁺) in the lung (e) and spleen (f). Data for all graphs are presented as means ± s.d. Statistical significances are indicated as follows: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns (P > 0.05), Mann–Whitney test. CTRL, control group.

Back to article page